Last10K.com

Oncobiologics, Inc. (ONS) SEC Filing 10-K Annual report for the fiscal year ending Saturday, September 30, 2017

Oncobiologics, Inc.

HISTORY TOOLS
CIK: 1649989 Ticker: ONS
Document And Entity Information - USD ($)
$ in Millions
12 Months Ended
Sep. 30, 2017
Dec. 27, 2017
Mar. 31, 2017
Document And Entity Information [Abstract]   
Entity Registrant NameOncobiologics, Inc.  
Entity Central Index Key0001649989  
Trading Symbolons  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Current Fiscal Year End Date--09-30  
Entity Filer CategorySmaller Reporting Company  
Entity Well-known Seasoned IssuerNo  
Entity Common Stock, Shares Outstanding 25,530,727 
Entity Public Float  $ 44.5
Document Type10-K  
Document Period End DateSep. 30, 2017  
Amendment Flagfalse  
Document Fiscal Year Focus2017  
Document Fiscal Period FocusFY  

View differences made from one year to another to evaluate Oncobiologics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncobiologics, Inc..

Continue

Assess how Oncobiologics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncobiologics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Redeemable Preferred Stock, Common Stock, Noncontrolling Interests And Stockholders' Equity (deficit)
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (detail Textuals 1)
Basis Of Presentation And Summary Of Significant Accounting Policies (detail Textuals)
Basis Of Presentation And Summary Of Significant Accounting Policies (details 1)
Basis Of Presentation And Summary Of Significant Accounting Policies (details)
Basis Of Presentation And Summary Of Significant Accounting Policies (policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (tables)
Collaboration Arrangements
Collaboration Arrangements (detail Textuals)
Commitments
Commitments (detail Textuals)
Commitments (details)
Commitments (tables)
Convertible Preferred Stock
Convertible Preferred Stock (detail Textuals)
Debt
Debt (detail Textuals)
Debt (details 1)
Debt (details 2)
Debt (details)
Debt (tables)
Fair Value Measurements
Fair Value Measurements (details 1)
Fair Value Measurements (details 2)
Fair Value Measurements (details)
Fair Value Measurements (tables)
Income Taxes
Income Taxes (detail Textuals)
Income Taxes (details 1)
Income Taxes (details 2)
Income Taxes (details 3)
Income Taxes (details)
Income Taxes (tables)
Liquidity
Liquidity (detail Textuals)
Organization And Operations
Property And Equipment
Property And Equipment (detail Textuals)
Property And Equipment (details 1)
Property And Equipment (details)
Property And Equipment (tables)
Related-party Transactions
Stock-based Compensation
Stock-based Compensation (detail Textuals 1)
Stock-based Compensation (detail Textuals 2)
Stock-based Compensation (detail Textuals 3)
Stock-based Compensation (detail Textuals)
Stock-based Compensation (details 1)
Stock-based Compensation (details 2)
Stock-based Compensation (details 3)
Stock-based Compensation (details 4)
Stock-based Compensation (details)
Stock-based Compensation (tables)
Stockholder Notes
Stockholder Notes (detail Textuals)
Stockholder Notes (details)
Stockholder Notes (tables)
Stockholders' Equity (deficit)
Stockholders' Equity (deficit) (detail Textuals 1)
Stockholders' Equity (deficit) (detail Textuals 2)
Stockholders' Equity (deficit) (detail Textuals)
Stockholders' Equity (deficit) (details)
Stockholders' Equity (deficit) (tables)
Subsequent Events
Subsequent Events (detail Textuals)

Material Contracts, Statements, Certifications & more

Oncobiologics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: ONS
CIK: 1649989
Form Type: 10-K Annual Report
Accession Number: 0001571049-17-008779
Submitted to the SEC: Fri Dec 29 2017 4:17:15 PM EST
Accepted by the SEC: Fri Dec 29 2017
Period: Saturday, September 30, 2017
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ons/0001571049-17-008779.htm